Chevron Corp vs BIO-TECHNE Corp — how do they compare? Chevron Corp trades at $181.72 (market cap $362.87B), while BIO-TECHNE Corp trades at $71.23 (market cap $11.12B). The key difference: Chevron Corp is far larger — about 32.6× BIO-TECHNE Corp's market cap, and Chevron Corp pays the higher dividend (3.91%). Which is the better fit depends on your goals.
| CVX | TECH | |
|---|---|---|
Market Cap | $362.87B | $11.12B |
Volume | 9,807,834 | — |
Sector | Energy | Health |
52-Week High | $211.14 | $71.38 |
52-Week Low | $146.72 | $43.31 |
Enterprise Value | $402.97B | $11.20B |
Dividend Yield | 3.91% | 0.45% |
Signals from Pluang's Aura AI — not financial advice
CVX trades at $181.77, up 3.04% today, with a bullish technical signal and strong analyst consensus. Recent earnings have consistently beaten estimates, though revenue and net income have declined year-over-year. The company maintains solid cash flow from operations and recently announced a $13.8 billion investment in Argentina's Vaca Muerta shale play, signaling growth commitment. High oil prices and geopolitical tensions are key near-term catalysts.
Outlook remains positive given Wall Street's $207.56 price target and 62% buy ratings, but risks include declining profit margins, volatile oil prices, and execution challenges on new projects. The stock offers value through dividends and strategic expansion, yet investors face headwinds from macroeconomic uncertainty and competitive pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →